Oncogene-induced senescence distinguishes indolent from aggressive forms of pulmonary and non-pulmonary Langerhans cell histiocytosis

Leukemia and Lymphoma

Volumn 55, Issue 11, 2014, Pages 2620-2626

  Chilosi, Marco ^a   Facchetti, Fabio ^b   Caliò, Anna ^a   Zamò, Alberto ^a   Brunelli, Matteo ^a   Martignoni, Guido ^a   Rossi, Andrea ^c   Montagna, Licia ^a   Piccoli, Paola ^a   Dubini, Alessandra ^d   Tironi, Andrea ^b   Tomassetti, Sara ^d   Poletti, Venerino ^d   Doglioni, Claudio ^e  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Verona General Hospital   (Italy)

^d MORGAGNI PIERANTONI HOSPITAL   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

BRAF mutation; P16INK4a; P21CIP1 WAF1; PLCH; Senescence in LCH

Indexed keywords

B RAF KINASE; B RAF KINASE V600E; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HAIRY CELL LEUKEMIA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LANGERHANS CELL HISTIOCYTOSIS; MALE; METASTATIC MELANOMA; ONCOGENE; PATHOGENESIS; PREVALENCE; PROTEIN EXPRESSION; PULMONARY LANGERHANS CELL HISTIOCYTOSIS; PYROSEQUENCING; SENESCENCE; THYROID CARCINOMA; CELL AGING; GENETICS; INFANT; LUNG; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CELL AGING; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA MUTATIONAL ANALYSIS; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LUNG; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROTO-ONCOGENE PROTEINS B-RAF; YOUNG ADULT;

EID: 84905657472     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.887713     Document Type: Article

References (73)

1. Nezelof C, Basset F. Langerhans cell histiocytosis research. Past, present, and future. Hematol Oncol Clin North Am 1998;12:385-406.
2. Geissmann F, Lepelletier Y, Fraitag S, et al. Dif erentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001; 97: 1241-1248.
3. Chikwava K, Jafe R. Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr Dev Pathol 2004;7:607-614.
4. Nezelof C, Basset F. Anhypothesis Langerhanscell histiocytosis: the failure of the immune system to switch from an innate to an adaptive mode. Pediatr Blood Cancer. 2004;42:398-400.
5. Badalian-Very G, Vergilio JA, Degar BA, et al. Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol 2012;156:163-172.
6. da Costa CE, Annels NE, Faaij CM, et al. Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis. J Exp Med 2005;201:687-693.
7. Thomas JA, Janossy G, Chilosi M, et al. Combined immunological and histochemical analysis of skin and lymph node lesions in histiocytosis X. J Clin Pathol 1982; 35: 327-337.
8. Yu RC, Chu C, Buluwela L, et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 1994; 343: 767-768.
9. Willman CL, Busque L, Grifth BB, et al. Langerhans'-cell histiocytosis (histiocytosis X)-a clonal proliferative disease. N Engl J Med 1994;331:154-160.
10. Magni M, Di Nicola M, Carlo-Stella C, et al. Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. Leuk Res 2002;26:1131-1133.
11. Chen W, Wang J, Wang E, et al. Detection of clonal lymphoid receptor gene rearrangements in langerhans cell histiocytosis. Am J Surg Pathol 2010;34:1049-1057.
12. Willman CL. Detection of clonal histiocytes in Langerhans cell histiocytosis: biology and clinical signif cance. Br J Cancer Suppl 1994;23:S29-S33.
13. Arico M, Nichols K, Whitlock JA, et al. Familial clustering of Langerhans cell histiocytosis. Br J Haematol 1999;107:883-888.
14. Katz AM, Rosenthal D, Jakubovic HR, et al. Langerhans cell histiocytosis in monozygotic twins. J Am Acad Dermatol 1991;24:32-37.
15. Bonetti F, Knowles DM 2nd, Chilosi M, et al. A distinctive cutaneous malignant neoplasm expressing the Langerhans cell phenotype. Synchronous occurrence with B-chronic lymphocytic leukemia. Cancer 1985;55:2417-2425.
16. Bonetti F, Chilosi M, Menestrina F, et al. Blastic OKT6-positive proliferation preceding malignant histiocytosis. Histol Histopathol 1986;1:391-397.
17. Ratei R, Hummel M, Anagnostopoulos I, et al. Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans'cell sarcoma: evidence for hematopoietic plasticity. Haematologica 2010;95:1461-1466.
18. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; 116: 1919-1923.
19. Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS One 2012;7:e33891.
20. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63: 4561-4567.
21. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-2315.
22. Ikenoue T, Hikiba Y, Kanai F, et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003; 63: 8132-8137.
23. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012;120:2700-2703.
24. Kumar R, Angelini S, Snellman E, et al. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004;122:342-348.
25. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-724.
26. Bosmuller H, Fischer A, Pham DL, et al. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Hum Pathol 2013; 44: 329-335.
27. Ilie M, Long E, Hofman V, et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 2013;24:742-748.
28. Mallette FA, Ferbeyre G. The DNA damage signaling pathway connects oncogenic stress to cellular senescence. Cell Cycle 2007; 6: 1831-1836.
29. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat Rev Cancer 2008; 8: 512-522.
30. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007;130:223-233.
31. Gray-Schopfer VC, Cheong SC, Chong H, et al. Cellularsenescence in naevi and immortalisation in melanoma: a role for p16? Br J Cancer 2006;95:496-505.
32. Martinelli P, Bonetti P, Sironi C, et al. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway. Blood 2011; 117: 6617-6626.
33. Subbiah V, Subbiah IM. Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. Ann Hematol 2013; 92:1149.
34. Vassallo R, Ryu JH. Pulmonary Langerhans'cell histiocytosis. Clin Chest Med 2004;25:561-571.
35. Travis WD, Borok Z, Roum JH, et al. Pulmonary Langerhans cell granulomatosis (histiocytosis X). A clinicopathologic study of 48 cases. Am J Surg Pathol 1993;17:971-986.
36. Yousem SA, Colby TV, Chen YY, et al. Pulmonary Langerhans'cell histiocytosis: molecular analysis of clonality. Am J Surg Pathol 2001;25:630-636.
37. Yousem SA, Dacic S, Nikiforov YE, et al. Pulmonary Langerhans cell histiocytosis: prof ling of multifocal tumors using next-generation sequencing identif es concordant occurrence of BRAF V600E mutations. Chest 2013;143:1679-1684.
38. Skorokhod A, Capper D, von Deimling A, et al. Detection of BRAF V600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1. J Am Acad Dermatol 2012;67:488-491.
39. Langerhans cells sarcoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classif cation of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p 360.
40. Arcila M, Lau C, Nafa K, et al. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011;13:64-73.
41. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012;120:28-34.
42. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011;122:11-19.
43. Capper D, Berghof AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1, 120 tumor tissue samples of patients with brain metastases. Acta Neuropathol 2012;123:223-233.
44. Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. Am J Surg Pathol 2012;36:1796-1800.
45. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol 2013;37:61-65.
46. Schouten B, Egeler RM, Leenen PJ, et al. Expression of cell cycle-related gene products in Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2002;24:727-732.
47. Petersen BL, Rengtved P, Bank MI, et al. High expression of markers of apoptosis in Langerhans cell histiocytosis. Histopathology 2003;42:186-193.
48. Bank MI, Rengtved P, Carstensen H, et al. p53 expression in biopsies from children with Langerhans cell histiocytosis. J Pediatr Hematol Oncol 2002;24:733-736.
49. Kim SY, Kim HJ, Park MR, et al. Role of p16 in the pathogenesis of Langerhans cell histiocytosis. Korean J Hematol 2010;45:247-252.
50. Kansal R, Quintanilla-Martinez L, Datta V, et al. Identif cation of the V600D mutation in exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. Genes Chromosomes Cancer 2013;52:99-106.
51. Vredeveld LC, Possik PA, Smit MA, et al. Abrogationof BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 2012; 26: 1055-1069.
52. Brabencova E, Tazi A, Lorenzato M, et al. Langerhans cells in Langerhans cell granulomatosis are not actively proliferating cells. Am J Pathol 1998;152:1143-1149.
53. Zheng QH, Ma LW, Zhu WG, et al. p21Waf1/Cip1 plays a critical role in modulating senescence through changes of DNA methylation. J Cell Biochem 2006;98:1230-1248.
54. Yasaei H, Gilham E, Pickles JC, et al. Carcinogen-specific mutational and epigenetic alterations in INK4A, INK4B and p53 tumour-suppressor genes drive induced senescence bypass in normal diploid mammalian cells. Oncogene 2013;32:171-179.
55. da Costa CE, Egeler RM, Hoogeboom M, et al. differences in telomerase expression by the CD1a+ cells in Langerhans cell histiocytosis reffect the diverse clinical presentation of the disease. J Pathol 2007;212:188-197.
56. Bechan GI, Meeker AK, De Marzo AM, et al. Telomere length shortening in Langerhans cell histiocytosis. Br J Haematol 2008;140: 420-428.
57. Vizioli MG, Possik PA, Tarantino E, et al. Evidence of oncogene-induced senescence in thyroid carcinogenesis. Endocr Relat Cancer 2011;18:743-757.
58. Jacob K, Quang-Khuong DA, Jones DT, et al. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res 2011;17:4650-4660.
59. Zuckerman V, Wolyniec K, Sionov RV, et al. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J Pathol 2009;219:3-15.
60. Marchal J, Kambouchner M, Tazi A, et al. Expression of apoptosis-regulatory proteins in lesions of pulmonary Langerhans cell histiocytosis. Histopathology 2004;45:20-28.
61. Young AR, Narita M. SASP reffects senescence. EMBO Rep 2009;10:228-230.
62. Kuilman T, Peeper DS. Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer 2009; 9: 81-94.
63. Arico M. Langerhans cell histiocytosis: too many cytokines, not enough gene regulation? Pediatr Blood Cancer 2006; 47: 118-119.
64. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005;120:513-522.
65. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729-740.
66. Coppe JP, Desprez PY, Krtolica A, et al. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol 2010;5:99-118.
67. Tazi A, Moreau J, Bergeron A, et al. Evidence that Langerhans cells in adult pulmonary Langerhans cell histiocytosis are mature dendritic cells: importance of the cytokine microenvironment. J Immunol 1999;163:3511-3515.
68. de Graaf JH, Tamminga RY, Dam-Meiring A, et al. The presence of cytokines in Langerhans' cell histiocytosis. J Pathol 1996;180: 400-406.
69. Egeler RM, Favara BE, van Meurs M, et al. Dif erential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 1999;94:4195-4201.
70. Annels NE, Da Costa CE, Prins FA, et al. Aberrant chemokine receptor expression and chemokine production by Langerhans cells underlies the pathogenesis of Langerhans cell histiocytosis. J Exp Med 2003;197:1385-1390.
71. Amir G, Weintraub M. Association of cell cycle-related gene products and NF-kappaB with clinical parameters in Langerhans cell histiocytosis. Pediatr Blood Cancer 2008;50:304-307.
72. Garabedian L, Struyf S, Opdenakker G, et al. Langerhans cell histiocytosis: a cytokine/chemokine-mediated disorder? Eur Cytokine Netw 2011;22:148-153.
73. Salminen A, Kauppinen A, Kaarniranta K. Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal 2012; 24: 835-845.